Caris Life SciencesvsJohnson & Johnson

CAI and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CAI

Caris Life Sciences, Inc.

$20.16

Value $5.7B

+3.28%
CAI's page

Caris Life Sciences (CAI) has a market value of $5.7B and Johnson & Johnson (JNJ) $643B. Over the last year, with dividends, CAI moved -15.2% and JNJ +36.4%. The P/E is 59.3 for CAI and 40.0 for JNJ. Dividend yield: CAI none, JNJ 1.98%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CAI$5.7B

    JNJ$643B

    JNJ is 113 times CAI

  • Revenue, 12 months

    CAI$1.0B

    JNJ$99.3B

    JNJ is 95 times CAI

  • Net income, 12 months

    CAI$96M

    JNJ$16.1B

    JNJ is 168 times CAI

  • Operating margin

    CAI13.4%

    JNJ–

  • ROIC

    CAI11.5%

    JNJ12.4%

    0.9 points apart

  • P/E

    CAI59.3

    JNJ40.0

    CAI is 1.5 times JNJ

  • Dividend yield

    CAI0.0%

    JNJ2.0%

    2.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CAI-15.2%

JNJ+36.5%

75100125DecFebAprJunAugOct
Returns by period
PeriodCAIWith dividendsJNJWith dividends
1 year since November 18, 2025-15.2%Price -15.2%+36.4%Price +33.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CAICaris Life SciencesJNJJohnson & Johnson

Valuation

CAIJNJ
Valuation
Price$20.16$266.87
Market value$5.7B$643B
Enterprise value (EV)–$671B
P/E59.340.0
P/E, 5-year median–21.9
P/B8.97.9
EV/EBIT–37.8
Free cash flow yield0.5%3.2%

Results and growth

CAIJNJ
Results and growth
Revenue, 12 months$1.0B$99.3B
Net income, 12 months$96M$16.1B
Free cash flow, 12 months$29M$20.6B
Earnings per share, 12 months$0.34$6.59
Revenue growth, year on year97.0%6.1%
Revenue growth a year, past+62.9%over 2 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CAIJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin13.4%–
Net margin9.2%16.2%
ROIC11.5%12.4%
ROE16.7%19.7%

Balance sheet

CAIJNJ
Balance sheet
Cash–$17.2B
Total debt–$44.7B
Net debt / EBITDA–1.1
Interest cover3.3×18.0×

Dividends and buybacks

CAIJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield0.0%0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CAI or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Caris Life Sciences or Johnson & Johnson?

By market value, Johnson & Johnson ($643B) is about 112.9 times Caris Life Sciences ($5.7B), at today's prices.

How did CAI and JNJ stock do over the last 1 years?

Since November 18, 2025, CAI's price moved -15.2% and JNJ's +33.4%. With dividends: CAI -15.2% (-15.2% a year), JNJ +36.4% (+36.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, CAI or JNJ?

The dividend yield at today's price is none for Caris Life Sciences and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of CAI and JNJ?

At today's price, the P/E is 59.3 for CAI and 40.0 for JNJ. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Caris Life Sciences or Johnson & Johnson?

Over the last twelve months, the net margin was 9.2% for Caris Life Sciences and 16.2% for Johnson & Johnson, and the operating margin 13.4% and –. Revenue was $1.0B and $99.3B.

Which is the better investment, Caris Life Sciences or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.